DominickJosephAngiolilloMD

Cardiology • Jacksonville, FL

Adult Congenital Heart Disease, Interventional Cardiology

Professor of Medicine, University of Florida College of Medicine

Join to view full profile

Dr. Angiolillo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Angiolillo's full profile

Already have an account?

Office
655 W 8th St
# Ufjp
Jacksonville, FL 32209
Phone+1 904-244-3660

Fax+1 904-244-3425

Summary

DOMINICK J. ANGIOLILLO, MD, PHD, FACC, FESC, FSCAI is a Professor of Medicine with Tenure status at the University of Florida. He is also the Director of Cardiovascular Research, Program Director, of the Interventional Cardiology Fellowship program, and Staff Cardiologist and Interventional Cardiologist at the University of Florida Health System. Dr. Angiolillo is triple board certified by the American Board of Internal Medicine (Internal Medicine, Cardiovascular Disease, Interventional Cardiology). Much of Dr. Angiolillo’s professional career has been devoted to cardiovascular research in the field of interventional cardiology and acute coronary syndrome. His largest national and international recognition has been for his pivotal contributions in the field of thrombosis. Since 2014 he has been in the top 1 percent of most-cited researchers worldwide according to Clarivate Analytics (formerly Thomson Reuters’ list of The World’s Most Influential Scientific Minds). Dr. Angiolillo has made major scientific contributions to many medical and cardiovascular journals, as well as textbooks of cardiovascular medicine. His leadership role as an academic clinician scientist has allowed to him to nurture and promote career growth and development of many young trainees pursuing both academic and clinical careers in the United States and abroad. Dr. Angiolillo is an active member of many cardiovascular societies in the Unites States and Europe.

Education & Training

University of FloridaFellowship, Cardiovascular Disease, 2004 - 2007
University of Cattolica del Sacro CuoreClass of 1997

Certifications & Licensure

FL State Medical License 2007 - 2025
American Board of Internal Medicine Cardiovascular Disease
American Board of Internal Medicine Interventional Cardiology

Awards, Honors, & Recognition

Fellow (FACC) American College of Cardiology

Clinical Trials

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting Start of enrollment: 2008 Sep 01
Unknown status
Phase 4
Comparison of Intravenous Adenosine Infusion With Regadenoson Bolus for Inducing Maximal Coronary Hyperemia Start of enrollment: 2010 Jul 01
Completed
Phase 1
PPI and Clopidogrel Response Start of enrollment: 2009 Mar 01
Completed
Phase 1
Prasugrel Re-load Strategies Start of enrollment: 2010 Aug 01
Completed
Phase 4
Aspirin Dosing in Diabetic Patients Start of enrollment: 2009 Jan 01
Completed
Phase 4
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles Start of enrollment: 2013 Jan 01
Completed
Not Applicable
Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy Start of enrollment: 2012 Feb 01
Completed
Not Applicable
Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease Start of enrollment: 2012 Jan 01
Completed
Not Applicable
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes Start of enrollment: 2013 Feb 01
Completed
Not Applicable
High Ticagrelor Loading Dose in STEMI Start of enrollment: 2013 Sep 01
Completed
Phase 2
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Start of enrollment: 2013 Sep 15
Completed
Phase 4
AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN Start of enrollment: 2013 Dec 01
Completed
Not Applicable
Pharmacodynamic Evaluation of Switching From Prasugrel to Ticagrelor Start of enrollment: 2014 Mar 01
Completed
Not Applicable
A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients Undergoing PCI With CYP2C19 Loss-of-function: Start of enrollment: 2014 Mar 01
Completed
Phase 4
In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients Start of enrollment: 2014 Apr 01
Completed
Not Applicable
Pharmacological Effects of Crushing Prasugrel in STEMI Patients Start of enrollment: 2014 Oct 01
Completed
Phase 4
Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease Start of enrollment: 2014 Dec 01
Completed
Phase 4
Impact of Chronic Kidney Disease on the Effects of Ticagrelor in Patients With Diabetes and Coronary Artery Disease Start of enrollment: 2016 Feb 01
Completed
Phase 4
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor Start of enrollment: 2016 Feb 01
Completed
Phase 4
Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus Start of enrollment: 2016 Mar 25
Completed
Phase 4
Edoxaban in Patients With Coronary Artery Disease on Dual Antiplatelet Therapy With Aspirin and Clopidogrel Start of enrollment: 2016 Mar 01
Completed
Phase 4
Effect of D-allulose in Addition to Oral Sucrose Load Start of enrollment: 2016 Aug 01
Completed
Phase 2
Implementation of CYP2C19 Genotyping to Guide Antiplatelet Therapy Start of enrollment: 2016 May 01
Completed
Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity Start of enrollment: 2017 Oct 03
Completed
Phase 4
Low Maintenance Dose Ticagrelor Versus Clopidogrel in Diabetes Patients Undergoing PCI Start of enrollment: 2018 Mar 14
Completed
Phase 4
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study Start of enrollment: 2018 May 30
Completed
Phase 4
Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies Start of enrollment: 2019 Jan 14
Completed
Phase 4
Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Start of enrollment: 2019 Sep 06
Completed
Phase 4
Tailoring P2Y12 Inhibiting Therapy in Patients Requiring Oral Anticoagulation After PCI Start of enrollment: 2020 Dec 08
Recruiting
Phase 4
Ticagrelor With and Without Aspirin in Patients With Diabetes Mellitus Start of enrollment: 2021 Mar 31
Active, not recruiting
Phase 4
VerifyNow® PRUTest® Cardiovascular Population Expected Values On-Drug Study Start of enrollment: 2016 Sep 06
Completed
Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery Start of enrollment: 2018 Nov 21
Unknown status
Roles: Contact
Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI Start of enrollment: 2023 Feb 15
Recruiting
Phase 4
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

339 citations
Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the Gauging Responsiveness with a VerifyNow P2Y1...
Matthew J. Price, Dominick J. Angiolillo, Paul S. Teirstein, Elizabeth O. Lillie, Steven V. Manoukian
Circulation. 2011-09-06
16 citations
Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience.
Roberta Rossini, Giulia Masiero, Claudia Fruttero, Enrico Passamonti, Elba Calvaruso
TH Open. 2020-10-01
313 citations
Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial.
Dominick J. Angiolillo, Michael S. Firstenberg, Matthew J. Price, Pradyumna E. Tummala, Martin Hutyra
JAMA. 2012-01-18

Journal Articles

Reply P2Y12 Inhibitor–Based Monotherapy: Optimal Duration and Ideal Agent
Dominick Angiolillo, MD, JACC: Cardiovascular Imaging
Coronary Effect of a Contrast Modulation System on Contrast Media Use and the Rate of Acute Kidney Injury After Coronary Angiography
Somjot Brar, Hitinder S Gurm, Barry Bertolet, Anand Prasad, Dominick J Angiolillo, Roxana Mehran, George Dangas, Wayne Batchelor, Gregg W Stone, ScienceDirect
Research Letter Ticagrelor Versus Clopidogrel for Recovery of Vascular Function Immediately After Successful Chronic Coronary Total Occlusion Recanalization: A Randomi...
Dominick Angiolillo, MD, ScienceDirect
Standardized Classification and Framework for Reporting, Interpreting, and Analysing Medication Non-Adherence in Cardiovascular Clinical Trials: A Consensus Report fro...
Dominick J Angiolillo, Gregg W Stone, Roxana Mehran, Deepak L Bhatt, Usman Baber, European Heart Journal
Aspirin-Free Strategies in Cardiovascular Disease and Cardioembolic Stroke Prevention
Dominick J Angiolillo, Francesco Franchi, George Dangas, Usman Baber, C Michael Gibson, Deepak L Bhatt, Nature
Join now to see all

Lectures

Take Home for Clinicians: DM and STEMI
CRF Transcatheter Cardiovascular Therapeutics - Annual Symposium 2019 - Miami, FL - 9/26/2019
Cardioprevention in Primary Care: Where Does Aspirin Fit In?
Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective
2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
Triple-doubles in Clinical Practice: Should 'Double Therapy' Replace 'Triple therapy' When Anticoagulation and Antiplatelet Therapy are Needed?
2019 ACC Scientific Session & Expo, New Orleans - 3/18/2019
Coronary Artery Disease Challenges in 2019: Cardiovascular Update for the Clinician-
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Deep Dive I
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
STEMI vs NSTEMI vs STABLE CAD Post PCI Optimal Antithrombotics DAPT Stent Complexity Comorbidities and NOACs Role
2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Join now to see all

Authored Content

Reply P2Y12 Inhibitor–Based Monotherapy: Optimal Duration and Ideal AgentSeptember 2020
Ticagrelor with or Without Aspirin in High-Risk Patients with Diabetes Mellitus Undergoing Percutaneous Coronary InterventionMay 2020
Ticagrelor with or Without Aspirin in High-Risk Patients with Diabetes Mellitus Undergoing Percutaneous Coronary InterventionMay 2020
Ticagrelor with or Without Aspirin in High-Risk Patients with Diabetes Mellitus Undergoing Percutaneous Coronary InterventionMay 2020
Pharmacogenomic Testing to Select Antiplatelet TherapyApril 2018
High on-Treatment Platelet Reactivity and Outcome in Elderly with Non ST-Segment Elevation Acute Coronary Syndrome - Insight from the GEPRESS StudyMarch 2018
The Quest for the Optimal Periprocedural Antithrombotic Treatment Strategy in ACS Patients Undergoing PCIMarch 2018
Ticagrelor for Secondary Prevention of Atherothrombotic Events in Patients with Multivessel Coronary DiseaseJanuary 2018
Join now to see all

Press Mentions

Aspirin Hypersensitivity in Patients with Atherosclerotic Cardiovascular DiseaseOctober 21st, 2024
Prolocor, Slingshot Bioscience Publish Paper on Prognostic Tool to Help Assess Thrombosis RiskSeptember 10th, 2024
Platelet Reactivity Score May Predict Heart Attack, Stroke Risk Beyond BP, CholesterolAugust 20th, 2024
Join now to see all